<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954521</url>
  </required_header>
  <id_info>
    <org_study_id>KY-QT-201905</org_study_id>
    <nct_id>NCT04954521</nct_id>
  </id_info>
  <brief_title>Anlotinib for Hepatocellular Carcinoma</brief_title>
  <acronym>AFHC</acronym>
  <official_title>A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Zhuang Autonomous Region People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Zhuang Autonomous Region People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe and explore the effect of single or combined&#xD;
      treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in&#xD;
      the real world, and to summarize the treatment experience of a wide range of people.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">July 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>From date of admission until the date of death from any cause, assessed up to 24 months</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>This is an observational study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced liver cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: â‰¥ 18 years old, male or female;&#xD;
&#xD;
          2. Patients with advanced liver cancer were diagnosed;&#xD;
&#xD;
          3. Patients assessed by doctors to benefit from single or combined treatment of arotinib;&#xD;
&#xD;
          4. Patients volunteered to join the project.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kehe Mr Chen, doctor</last_name>
      <phone>0086-15678820154</phone>
      <email>chenkehe20216666@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Zhuang Autonomous Region People's Hospital</investigator_affiliation>
    <investigator_full_name>Kehe Chen</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

